TGR-678
- Generic Name
- TGR-678
TGRX-678 Phase I Oral Pharmacokinetic Study
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06697899
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06453902
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06088888
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05434312
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath